Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ALTERITY THERAPEUTICS LTD files with the SEC in its annual reports.
In AUD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.14
0.13
0.2
Research and development
9.59
5.7
6.7
13
10.1
12.3
14.7
13.2
18.6
14.4
General and administrative
1.09
0.68
0.9
0.8
0.67
0.72
0.91
1.03
1.03
0.52
Interest expense
0
Pre-tax income
-7.73
-7.54
-8.27
-12.3
-13.5
-15.3
-12.8
-13.7
-19.1
-12.1
Income tax
0
0
0
0
0.07
0.1
0.05
0.07
Net income
-7.73
-7.54
-8.27
12.3
13.5
15.3
12.8
13.8
-19.1
-12.1
EPS, basic
-1.45
-1.41
-1.55
-2.00
-1.50
-0.90
-0.53
-0.57
-0.52
-0.19
EPS, diluted
-1.45
-1.41
-1.55
-2.00
-1.50
-0.90
-0.53
-0.57
-0.52
-0.19
Balance sheet
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
28.6
21.9
15.2
14.4
9.2
28.1
34.8
15.8
12.6
33.2
Receivables
3.04
3.15
4.83
0.06
4.28
4.73
8.67
4.04
3.94
Total current assets
25.3
18.7
19.9
9.84
33.5
41.1
27
19
45.9
Property, plant and equipment
0.03
0.07
0.05
0.04
0.03
0.1
0.06
0.03
0
Lease right-of-use assets
0.03
0.07
0.12
0.21
0.15
0.15
Total assets
25.3
18.7
19.9
9.91
33.6
41.4
27.3
19.2
46
Accounts payable
0.89
2.06
2.72
2.07
2.5
5.08
3.52
4.62
2.58
Total current liabilities
1.59
2.64
3.32
2.71
3.07
5.82
4.38
5.37
3.53
Lease liabilities
0
0.04
0.06
0.1
0.05
0.09
Total liabilities
1.59
2.64
3.36
2.76
3.12
5.89
4.5
5.43
3.62
Retained earnings
125
-123
-130
-141
-154
170
-182
-195
-214
-226
Shareholders' equity
-195
-214
-226
Total equity
31.4
23.7
16.1
16.6
7.15
30.5
35.5
22.8
13.8
42.4
Total liabilities and equity
25.3
18.7
19.9
9.91
33.6
41.4
27.3
19.2
46
Cash flow statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-7.73
-7.54
-8.27
-12.3
-13.5
-15.3
-12.8
-13.8
-19.1
-12.1
Cash from operations
-7.42
-5.87
-6.25
-14
-9.43
-17.3
-12.3
-20
-12.6
-11.5
Capital expenditures
-0
-0.03
-0.06
-0.01
-0.02
-0.01
-0.09
-0.01
-0.01
Cash from investing
-0
-0.03
-0.02
-0.01
-0.02
-0.01
-0.09
-0.04
-0.01
-7.5
Cash from financing
-0.16
-0.11
12.7
3.98
36.7
16.3
0.12
9.22
39.7
Exchange rate effect
0.95
0.66
-0.28
0.4
0.26
-0.43
2.81
0.91
0.26
-0.2
Free cash flow
-7.42
-5.89
-6.31
-14
-9.45
-17.3
-12.4
-20
-12.6
Interest paid
0
0
0
0
0.01
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-37.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
139.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
3.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
36.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
13.0x
Current assets / current liabilities.
Quick ratio
10.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.38x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-A$0.19
Net income per basic share, as reported (split-adjusted).
Was ALTERITY THERAPEUTICS LTD profitable in fiscal 2025?
No. It reported a net loss of A$12.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.